Clinicopathological characteristics and outcomes of chinese patients with scanty immune deposits lupus nephritis: A large cohort study from a single center

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Li, Qiuyu ^a,b,c,d   Song, Di ^a,b,c,d   Wang, Fengmei ^a,b,c,d   Tan, Ying ^a,b,c,d   Yu, Feng ^a,b,c,d   Zhao, Minghui ^a,b,c,d  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AZATHIOPRINE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; PROPERDIN; ANTIGEN ANTIBODY COMPLEX;

ADULT; ALOPECIA; ANEMIA; ARTHRITIS; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CREATININE BLOOD LEVEL; FEMALE; FEVER; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNE COMPLEX DEPOSITION; INFLAMMATION; KIDNEY BIOPSY; LEUKOCYTURIA; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MOUTH ULCER; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PHOTOSENSITIVITY; RASH; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT FAILURE; ANTIGEN ANTIBODY COMPLEX; BIOPSY; BLOOD; CHINA; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGEN-ANTIBODY COMPLEX; BIOPSY; CHINA; CREATININE; FEMALE; HUMANS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84896885548     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/212597     Document Type: Article

References (43)

1. Charney D. A., Nassar G., Truong L., Nadasdy T., 'Pauci-immune' proliferative and necrotizing glomerulonephritis with thrombotic microangiopathy in patients with systemic lupus erythematosus and lupus-like syndrome. The American Journal of Kidney Diseases 2000 35 6 1193 1206 2-s2.0-0034116814
2. Fayaz A., Pirson Y., Cosyns J. P., Yango J., Lambert M., Pauci-immune necrotizing and crescentic glomerulonephritis in a patient with systemic lupus erythematosus. Clinical Nephrology 2008 69 4 290 293 2-s2.0-42049085043
3. Kraft S. W., Schwartz M. M., Korbet S. M., Lewis E. J., Glomerular podocytopathy in patients with systemic lupus erythematosus. Journal of the American Society of Nephrology 2005 16 1 175 179 2-s2.0-21644468026 10.1681/ASN.2004050350
4. Weening J. J., D'Agati V. D., Schwartz M. M., Seshan S. V., Alpers C. E., Appel G. B., Balow J. E., Bruijn J. A., Cook T., Ferrario F., Fogo A. B., Ginzler E. M., Hebert L., Hill G., Hill P., Jennette J. C., Kong N. C., Lesavre P., Lockshin M., Looi L. M., Makino H., Moura L. A., Nagata M., The classification of glomerulonephritis in systemic lupus ereythematosus revisited. Kidney International 2004 65 521 530 2-s2.0-10744226747
5. Falk R. J., Jennette J. C., Nachman P. H., Brenner B. M., Primary glomerular disease. The Kidney 2004 7th Philadelphia, Pa, USA Saunders 1293 1380
6. Hochberg M. C., Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 1997 40 9, article 1725 2-s2.0-0031229830
7. Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chang C. H., Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis and Rheumatism 1992 35 6 630 640 2-s2.0-0026777352 10.1002/art.1780350606
8. Liang M. H., Socher S. A., Larson M. G., Schur P. H., Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis and Rheumatism 1989 32 9 1107 1118 2-s2.0-0024419180
9. Wang J., Hu W., Xie H., Zhang H., Chen H., Zeng C., Liu Z., Li L., Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007 16 9 707 712 2-s2.0-34948895412 10.1177/0961203307081340
10. Ginzler E. M., Dooley M. A., Aranow C., Kim M. Y., Buyon J., Merrill J. T., Petri M., Gilkeson G. S., Wallace D. J., Weisman M. H., Appel G. B., Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. The New England Journal of Medicine 2005 353 21 2219 2228 2-s2.0-28144433147 10.1056/NEJMoa043731
11. Chan T. M., Tse K. C., Tang C. S. O., Lai K. N., Li F. K., Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005 14 4 265 272 2-s2.0-15944410008 10.1191/0961203305lu2081oa
12. Wang H. Y., Cui T. G., Hou F. F., Ni Z. H., Chen X. M., Lu F. M., Xu F. F., Yu X. Q., Zhang F. S., Zhao X. Z., Zhao M. H., Wang G. B., Qian J. Q., Cai G. Y., Zhu T. Y., Wang Y. H., Jiang Z. P., Li Y. N., Mei C. L., Zou W. Z., Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008 17 7 638 644 2-s2.0-48249119614 10.1177/0961203308089408
13. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., Roth D., Sequential therapies for proliferative lupus nephritis. The New England Journal of Medicine 2004 350 10 971 980 2-s2.0-1442355581 10.1056/NEJMoa031855
14. Grootscholten C., Ligtenberg G., Hagen E. C., van den Wall Bake A. W. L., de Glas-Vos J. W., Bijl M., Assmann K. J., Bruijn J. A., Weening J. J., van Houwelingen H. C., Derksen R. H. W. M., Berden J. H. M., Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney International 2006 70 4 732 742 2-s2.0-33747082349 10.1038/sj.ki.5001630
15. Xin G., Zhao M. H., Wang H. Y., Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in Chinese patients with clinically suspected vasculitis. Clinical and Diagnostic Laboratory Immunology 2004 11 3 559 562 2-s2.0-2442640387 10.1128/CDLI.11.3.559-562.2004
16. Zadura A. F., Theander E., Blom A. M., Trouw L. A., Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers. Scandinavian Journal of Immunology 2009 69 4 374 380 2-s2.0-61849088306 10.1111/j.1365-3083.2009.02229.x
17. Nascimento E. J. M., Silva A. M., Cordeiro M. T., Brito C. A., Gil L. H. V. G., Braga-Neto U., Marques E. T. A., Alternative complement pathway deregulation is correlated with dengue severity. PLoS ONE 2009 4 8 2-s2.0-69449083760 10.1371/journal.pone.0006782 e6782
18. Förster-Waldl E., Cokoja L., Förster O., Maurer W., Mannose-binding lectin: comparison of two assays for the quantification of MBL in the serum of pediatric patients. Journal of Immunological Methods 2003 276 1-2 143 146 2-s2.0-0242585353 10.1016/S0022-1759(03)00019-X
19. Appel G. B., Pirani C. L., D'Agati V., Renal vascular complications of systemic lupus erythematosus. Journal of the American Society of Nephrology 1994 4 8 1499 1515 2-s2.0-0028376072
20. Markowitz G. S., D'Agati V. D., Classification of lupus nephritis. Current Opinion in Nephrology and Hypertension 2009 18 3 220 225 2-s2.0-67049116117 10.1097/MNH.0b013e328327b379
21. Austin H. A. III, Boumpas D. T., Vaughan E. M., Balow J. E., Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney International 1994 45 2 544 550 2-s2.0-0027976583
22. Austin H. A. III, Muenz L. R., Joyce K. M., Antonovych T. T., Balow J. E., Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney International 1984 25 4 689 695 2-s2.0-0021153603
23. Barnum S. R., Dahlback B., C4b-binding protein, a regulatory component of the classical pathway of complement, is an acute-phase protein and is elevated in systemic lupus erythematosus. Complement and Inflammation 1990 7 2 71 77 2-s2.0-0025148097
24. Blom A. M., Kask L., Dahlbäck B., CCP1-4 of the C4b-binding protein α -chain are required for factor I mediated cleavage of complement factor C3b. Molecular Immunology 2003 39 10 547 556 2-s2.0-0037210218 10.1016/S0161-5890(02)00213-4
25. Pavlov I. Y., de Forest N., Delgado J. C., Specificity of EIA immunoassay for complement factor Bb testing. Clinical Laboratory 2011 57 3-4 225 228 2-s2.0-79957816900
26. Watanabe H., Noguchi E., Shio K., Iwadate H., Kobayashi H., Ohira H., Usefulness of complement split product, Bb, as a clinical marker for disease activity of lupus nephritis. Fukushima Journal of Medical Science 2006 52 2 103 109 2-s2.0-34247862255
27. Ganter M. T., Brohi K., Cohen M. J., Shaffer L. A., Walsh M. C., Stahl G. L., Pittet J. F., Role of the alternative pathway in the early complement activation following major trauma. Shock 2007 28 1 29 34 2-s2.0-34250700510 10.1097/shk.0b013e3180342439
28. Meehan S. M., Chang A., Khurana A., Baligan R., Kadambi P. V., Javaid B., Pauci-immune and immune glomerular lesions in kidney transplants for systemic lupus erythematosus. Clinical Journal of the American Society of Nephrology 2008 3 5 1469 1478 2-s2.0-53749103491 10.2215/CJN.00790208
29. Abdellatif A. A., Waris S., Lakhani A., Kadikoy H., Haque W., Truong L. D., True vasculitis in lupus nephritis. Clinical Nephrology 2010 74 2 106 112 2-s2.0-77955726519
30. Li F. C., Hwang D. Y., Hung C. C., Chen H. C., Pauci-immune lupus nephritis: a case report. Kaohsiung Journal of Medical Sciences 2008 24 10 531 535 2-s2.0-60149087905
31. Yu F., Tan Y., Liu G., Wang S. X., Zou W. Z., Zhao M. H., Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney International 2009 76 3 307 317 2-s2.0-67651093947 10.1038/ki.2009.136
32. Nasr S. H., D'Agati V. D., Park H. R., Sterman P. L., Goyzueta J. D., Dressler R. M., Hazlett S. M., Pursell R. N., Caputo C., Markowitz G. S., Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clinical Journal of the American Society of Nephrology 2008 3 3 682 690 2-s2.0-44649136897 10.2215/CJN.04391007
33. Masani N. N., Imbriano L. J., D'Agati V. D., Markowitz G. S., SLE and rapidly progressive glomerulonephritis. The American Journal of Kidney Diseases 2005 45 5 950 955 2-s2.0-26944438025 10.1053/j.ajkd.2004.08.047
34. Buyon J. P., Tamerius J., Ordorica S., Young B., Abramson S. B., Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis and Rheumatism 1992 35 1 55 61 2-s2.0-0026580379
35. Buyon J. P., Tamerius J., Belmont H. M., Abramson S. B., Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis and Rheumatism 1992 35 9 1028 1037 2-s2.0-0026796030 10.1002/art.1780350907
36. Kerr L. D., Adelsberg B. R., Schulman P., Spiera H., Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis and Rheumatism 1989 32 11 1406 1413 2-s2.0-0024388462 10.1002/anr.1780321109
37. Sato N., Ohsawa I., Nagamachi S., Ishii M., Kusaba G., Inoshita H., Toki A., Horikoshi S., Ohi H., Matsushita M., Tomino Y., Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus 2011 20 13 1378 1386 2-s2.0-81555227097 10.1177/0961203311415561
38. Sánchez-Corral P., Bellavia D., Amico L., Brai M., de Córdoba S. R., Molecular basis or factor H and FHL-1 deficiency in an Italian family. Immunogenetics 2000 51 4-5 366 369 2-s2.0-0034127338
39. Nagy G., Brózik M., Varga L., Füst G., Kirschfink M., Kiss E., Gergely P., Usefulness of detection of complement activation products in evaluating SLE activity. Lupus 2000 9 1 19 25 2-s2.0-0343527958
40. Bao L., Haas M., Quigg R. J., Complement factor H deficiency accelerates development of lupus nephritis. Journal of the American Society of Nephrology 2011 22 2 285 295 2-s2.0-79551664780 10.1681/ASN.2010060647
41. Jennette J. C., Falk R. J., New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Current Opinion in Rheumatology 2008 20 1 55 60 2-s2.0-40349088701 10.1097/BOR. 0b013e3282f16c0a
42. Xiao H., Schreiber A., Heeringa P., Falk R. J., Jennette J. C., Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. American Journal of Pathology 2007 170 1 52 64 2-s2.0-33847052568 10.2353/ajpath.2007.060573
43. Xing G. Q., Chen M., Liu G., Zheng X., Jie E. J., Zhao M. H., Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. Journal of Clinical Immunology 2010 30 1 144 156 2-s2.0-77249145839 10.1007/s10875-009-9344-2